cyclo therapeutics presents encouraging preliminary safety data from ongoing pivotal phase 3 study and substudy for the treatment of niemann-pick disease type c1 (npc1)
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing...